Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
- Conditions
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 54
- Registration Number
- NCT02283775
- Locations
- 🇺🇸
Investigational Site Number 840011, Decatur, Illinois, United States
🇺🇸Investigational Site Number 840015, Salt Lake City, Utah, United States
🇺🇸Investigational Site Number 840005, Seattle, Washington, United States
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT02265510
- Locations
- 🇺🇸
Site 2, Nashville, Tennessee, United States
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT02228512
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT02206425
- Locations
- 🇺🇸
James Berenson, MD, Inc, West Hollywood, California, United States
🇺🇸cCARE Fresno, Fresno, California, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 57
- Registration Number
- NCT02185820
- Locations
- 🇮🇹
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Torino, Italy
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- Ajai Chari
- Target Recruit Count
- 35
- Registration Number
- NCT02176213
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Food Effect and CYP1A2 Induction Study in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 55
- Registration Number
- NCT02168205
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 775
- Registration Number
- NCT02164955
- Locations
- 🇧🇪
Centre Hospitalier Peltzer-La Tourelle, Verviers, Rue Du Parc 29, Belgium
🇧🇪Clinique Saint-Pierre, Ottignies, Belgium
🇬🇧Broomfield Hospital, Broomfield,Chelmsford, Essex, United Kingdom
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT02119468
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 38
- Registration Number
- NCT02103335
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.